Premium
Scaffold Vaccines for Generating Robust and Tunable Antibody Responses
Author(s) -
Najibi Alexander J.,
Dellacherie Maxence O.,
Shih TingYu,
Doherty Edward J.,
White Des A.,
BaulethRamos Tomás,
Stafford Alexander G.,
Weaver James C.,
Yeager Chyenne D.,
Seiler Benjamin T.,
Pezone Matthew,
Li Aileen W.,
Sarmento Bruno,
Santos Hélder A.,
Mooney David J.,
Gu Luo
Publication year - 2022
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202110905
Subject(s) - adjuvant , immune system , antigen , immunology , germinal center , immunization , antibody , materials science , biology , medicine , b cell
Traditional bolus vaccines often fail to sustain robust adaptive immune responses, typically requiring multiple booster shots for optimal efficacy. Additionally, these provide few opportunities to control the resulting subclasses of antibodies produced, which can mediate effector functions relevant to distinct disease settings. Here, it is found that three scaffold‐based vaccines, fabricated from poly(lactide‐ co ‐glycolide) (PLG), mesoporous silica rods, and alginate cryogels, induce robust, long‐term antibody responses to a model peptide antigen gonadotropin‐releasing hormone with single‐shot immunization. Compared to a bolus vaccine, PLG vaccines prolong germinal center formation and T follicular helper cell responses. Altering the presentation and release of the adjuvant (cytosine‐guanosine oligodeoxynucleotide, CpG) tunes the resulting IgG subclasses. Further, PLG vaccines elicit strong humoral responses against disease‐associated antigens HER2 peptide and pathogenic E. coli , protecting mice against E. coli challenge more effectively than a bolus vaccine. Scaffold‐based vaccines may thus enable potent, durable and versatile humoral immune responses against disease.